Repulsive Guidance Molecule B Deficiency Induces Gut Microbiota Dysbiosis and Increases the Susceptibility to Intestinal Inflammation in Mice
Overview
Affiliations
Imbalance of gut microbiota can induce or aggravate intestinal inflammation. To enhance our understanding of the molecular mechanisms of gut microbiota and inflammatory bowel disease (IBD), we studied the role of repulsive guidance molecule b (RGMb) in gut microbiota and colitis in mice. We generated Rgmb knockout mice and inducible Rgmb knockout mice and induced colitis using dextran sulfate sodium (DSS) in these mice. 16S ribosomal RNA (rRNA) high-throughput sequencing was performed to acquire the gut microbiota composition and abundance. We found that Rgmb deficiency significantly altered the diversity of gut microbiota and also induced dysbiosis. In sharp contrast to the balanced distribution of various bacteria in control mice, was almost exhausted in Rgmb-deficient mice under both basal and inflammatory conditions. Correlation analysis indicated that was negatively associated with inflammation in Rgmb-deficient mice with colitis. Similar results were obtained at the early inflammatory stage of colitis associated colon cancer (CAC). Taken together, our results reveal that Rgmb deficiency leads to dysbiosis of predominant gut microbiota under basal and inflammatory conditions. Rgmb-deficiency-mediated loss may render mice more susceptible to intestinal inflammation. Therefore, RGMb may be a novel potential target for reconstruction of the gut microbiota for the treatment of IBD.
Otalora-Otalora B, Payan-Gomez C, Lopez-Rivera J, Pedroza-Aconcha N, Arboleda-Mojica S, Aristizabal-Guzman C Cells. 2025; 14(1.
PMID: 39791702 PMC: 11720097. DOI: 10.3390/cells14010001.
Cao M, Cui B Cardiovasc Diabetol. 2024; 23(1):126.
PMID: 38614964 PMC: 11016216. DOI: 10.1186/s12933-024-02222-1.
The B7:CD28 family and friends: Unraveling coinhibitory interactions.
Burke K, Chaudhri A, Freeman G, Sharpe A Immunity. 2024; 57(2):223-244.
PMID: 38354702 PMC: 10889489. DOI: 10.1016/j.immuni.2024.01.013.
Shahbazi R, Yasavoli-Sharahi H, Alsadi N, Sharifzad F, Fang S, Cuenin C Int J Mol Sci. 2023; 24(19).
PMID: 37834058 PMC: 10572597. DOI: 10.3390/ijms241914610.
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park J, Gazzaniga F, Wu M, Luthens A, Gillis J, Zheng W Nature. 2023; 617(7960):377-385.
PMID: 37138075 PMC: 10219577. DOI: 10.1038/s41586-023-06026-3.